Cell Source, Inc.
CLCS · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2 | $2 | $2 | $1 |
| G&A Expenses | $0 | $3 | $2 | $3 |
| SG&A Expenses | $2 | $3 | $2 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4 | $4 | $4 | $4 |
| Operating Income | -$4 | -$4 | -$4 | -$4 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1 | -$1 | -$1 | -$1 |
| Pre-Tax Income | -$5 | -$5 | -$5 | -$5 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | -$5 | -$5 | -$5 |
| % Margin | – | – | – | – |
| EPS | -0.15 | -0.17 | -0.18 | -0.19 |
| % Growth | 11.8% | 5.6% | 5.3% | – |
| EPS Diluted | -0.15 | -0.17 | -0.18 | -0.19 |
| Weighted Avg Shares Out | 42 | 38 | 35 | 28 |
| Weighted Avg Shares Out Dil | 42 | 38 | 35 | 33 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $4 | $4 |
| EBITDA | -$4 | -$4 | $0 | -$0 |
| % Margin | – | – | – | – |